- European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Exelixis Inc's (NASDAQ: EXEL) Cabometyx (cabozantinib) in combination with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) for advanced renal cell carcinoma.
- Exelixis' partner Ipsen Pharma has exclusive rights to commercialize and develop Cabometyx outside of the U.S. and Japan.
- The positive opinion follows FDA approval for Cabometyx plus Opdivo as a first-line treatment of advanced renal cell carcinoma.
- Price Action: EXEL shares are 0.05% higher at $21.97, while BMY shares are down 0.2% at $61.9 on the last check Friday.
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
